PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Moderna chasing ‘holy grail’ of cancer prevention

Moderna CEO Stéphane Bancel says the company's personalized mRNA cancer vaccine could work in "more cancers than melanoma" and aims for FDA approval by 2027, with shares up 750% in 2026.

11sources
13articles
11velocity
+285%since first seen
5d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

Coverage of Moderna's cancer vaccine efforts quieted after a cluster of reports in early November 2026 highlighted promising trial data for a personalized melanoma vaccine and the company's stated goal of developing a universal cancer shot. Headlines at the time noted the therapy's potential to work across multiple cancer types and speculation about possible FDA approval in 2027. No subsequent headlines in the provided set indicate trial completion, regulatory action, or further clinical updates.

Epilogue added 1d ago, after coverage quieted.

The brief

Moderna is pursuing what the Financial Times calls the "holy grail" of cancer prevention with its personalized mRNA vaccine candidate mRNA-4157, also known as V940 or intismeran, developed in partnership with Merck. The therapy uses a patient's own tumor mutations to create a custom vaccine designed to train the immune system to recognize and attack cancer cells. It is being tested in combination with Merck's PD-1 inhibitor pembrolizumab (Keytruda).

According to the Financial Times, CEO Stéphane Bancel told investors the approach could work in "more cancers than melanoma" and that the company is also developing an off-the-shelf universal cancer vaccine. The Seoul Economic Daily reported that Moderna is moving beyond personalized vaccines to a universal shot. Pharmaceutical Technology noted Bancel sees a future for the personalized vaccine that could eclipse Keytruda, which generated $25 billion in sales in 2023.

Pembrolizumab, marketed as Keytruda by Merck, is a humanized monoclonal IgG4 antibody that blocks the PD-1 receptor, preventing its interaction with PD-L1 and PD-L2 and releasing immune inhibition against tumor cells. OC Academy notes it was approved by the FDA in September 2014 as a breakthrough therapy for metastatic melanoma and is also used for non-small cell lung carcinoma, Hodgkin lymphoma, urothelial carcinoma, and cutaneous squamous cell carcinoma. Common side effects occur in 20% or more of patients; serious adverse reactions include renal failure, dyspnoea, pneumonia, and cellulitis. Immune-mediated adverse effects include pneumonitis, colitis, hypophysitis, thyroid disorders, nephritis, and hepatitis.

Johns Hopkins Medicine and Newswise reported that cancer vaccines show promise for both treatment and prevention, with personalized neoantigen vaccines and preventive vaccines targeting viruses like HPV and hepatitis B, as well as vaccines for high-risk genetic syndromes such as Lynch syndrome. The Royal Examiner described the personalized vaccine as "made for one patient at a time" showing promise against melanoma.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (63% supported) Updated 4d ago.

Quick answers

What is Moderna's personalized cancer vaccine and how does it work?

Moderna's mRNA-4157 (V940/intismeran) is an mRNA-based personalized cancer vaccine developed with Merck. It uses a patient's own tumor mutations to create a custom vaccine that trains the immune system to recognize and attack cancer cells, and is given in combination with pembrolizumab (Keytruda).

What clinical results have been reported for the vaccine in melanoma?

In the Phase 2b KEYNOTE-942 trial with 157 high-risk stage III/IV melanoma patients, the combination of mRNA-4157 and pembrolizumab reduced the risk of recurrence or death by 49% compared to pembrolizumab alone, with a median follow-up of three years.

When could Moderna's cancer vaccine receive FDA approval?

The FDA granted Breakthrough Therapy Designation in February 2026. Moderna targets a potential approval in 2027, with a Phase 3 trial (KEYNOTE-942/INTerpath-002) currently enrolling approximately 1,089 patients.

Coverage (13)

Topics

Related trends

\n \n \n \n \n \n \n